Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

A MOTHER has revealed that she was unhappy and overweight so decided to start using Mounjaro. In just seven months, thanks to ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Bio-Techne surpasses profit expectations with significant growth in its research products, leading to the announcement of a ...

Hims & Hers continues to deliver strong revenue growth. Meanwhile, the company surprised investors by offering a long-term ...

Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce ...

A post-earnings rally in Hims & Hers Health Inc. has turned co-founder and Chief Executive Officer Andrew Dudum into a weight-loss billionaire.

GLP-1 medications like Ozempic, Wegovy and Mounjaro have gone from obscure diabetes treatments to front-page news thanks to ...

In the bankruptcy filing, WeightWatchers' parent company, WW International Inc., said nearly three-quarters of its creditors ...